271 results on '"Shames, D."'
Search Results
2. 1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC
3. P22.02 Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease
4. MA07.02 Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150
5. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
6. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer
7. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer
8. OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
9. Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: formulating recommendations in an environment of evolving clinical science
10. 1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
11. Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
12. MA03.05 BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer
13. An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK study
14. Dynamische, kontrastverstärkte (DCE-) MRI mit makromolekularem Kontrastmittel zur nicht-invasiven Differenzierung von Tumoren mit hoher, von Tumoren mit niedriger intrinsischer VEGF-Aktivität am experimentellen Tumormodell: PO576
15. Pulmonary oxygen toxicity: Demonstration of abnormal capillary permeability using contrast-enhanced MRI
16. The predictive value of preprocedural laboratory data in patients with coronary artery restenosis in various types of stents
17. MA04.10 Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC
18. PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC
19. Dissecting gastric cancer biology and how and when to use immunotherapy
20. MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC
21. P1.04-011 Development of Novel Blood-Based Biomarker Assays in 1L Advanced/Metastatic NSCLC: Blood First Assay Screening Trial (BFAST)
22. Thallium201 Myocardial Perfusion Scintigraphy for the Evaluation of Post Coronary Bypass Patients
23. LBA81_PR - Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
24. 1559P - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK study
25. 59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening
26. 85P - Dissecting gastric cancer biology and how and when to use immunotherapy
27. THE COMPARISON OF REGIONAL MORTALITY FROM CARDIOVASCULAR DISEASES IN THE YEARS 2006-2014 BY NOSOLOGICAL AND AGE-RELATED REGARDS
28. Reversible Versus Irreversible EGFR Tyrosine-Kinase Inhibitors for Non-Small-Cell Lung Cancer (NSCLC): a Preclinical and Pharmacokinetic Comparison
29. Prevalence and Prognostic Significance of Sodium-Dependent Phosphate Transporter 2B (Napi2B) Protein Expression in Non-Small Cell Lung Cancer (Nsclc)
30. Prevalence, Prognostic Significance, and Overlap of Actionable Biomarkers in Nsclc
31. Retraction Note: DNA methylation-associated inactivation of TGFβ-related genes, DRM/Gremlin, RUNX3, and HPP1 in human cancers
32. Domain of validity of the double isotope tracer method for measuring fractional zinc absorption: theoretical justification
33. NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition
34. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer
35. CMR 2007: 7.01: Development of new dendrimeric MRI contrast agents with poly(ethylene glycol) cores: toward the selection of the single best compound
36. CMR 2007: 2.04: Novel macromolecular iodinated contrast medium permits assays of cancer microvascular leakiness in response to anti-VEGF antibody using dynamic CT
37. CMR 2007: 2.02: Characterizing cancer microvasculature: correlations of dynamic macromolecular contrast media-enhanced MRI with microscopic morphology
38. Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: formulating recommendations in an environment of evolving clinical science
39. Charakterisierung chemisch induzierter mammärer Tumoren in einem Rattenmodell unter Einsatz des neuen MRT-Kontrastmittels Gadofluorine M
40. CMR 2005: 3.01: MRI tumor characterization using Gd–GlyMe–DOTA-perfluorooctylmannose conjugate (Gadofluorine M), a novel protein-avid contrast agent
41. 196P - Prevalence, Prognostic Significance, and Overlap of Actionable Biomarkers in Nsclc
42. 194P - Prevalence and Prognostic Significance of Sodium-Dependent Phosphate Transporter 2B (Napi2B) Protein Expression in Non-Small Cell Lung Cancer (Nsclc)
43. DNA methylation-associated inactivation of TGFβ-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers
44. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
45. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents.
46. Ca(2+)-force relationship of frog skeletal muscle: a dynamic model for parameter estimation
47. Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy.
48. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density.
49. Mapping Abnormal Synovial Vascular Permeability in Temporomandibular Joint Arthritis in the Rabbit Using MRI
50. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.